Facebook
  1. Home
  2. Solutions
  3. Site & Patient Solutions
  4. Sites

Sites

Support and structure for faster start-up, increased patient recruitment and consistent quality

Delivering benefits to patients and sites

We support all sites, from very experienced to research-naïve, reducing site burden to allow more time dedicated to patient care. Our site support can be customised to fit a particular protocol, or to fit individual site needs. From access to our global site network, to resourcing and engagement via Site Engagement Liaisons and Clinical Trial Liaisons, we can help sites operationlise their clinical research more efficiently, leading to faster timelines, better study data, and higher satisfaction for clinical trial participants.

Centralised support services

ICON offers sites dedicated support through centralised services, allowing us to absorb the risk and upfront costs of participating in a clinical trial. Our centralised support team provides the people and processes to facilitate rapid study start, including medical oversight, site feasibility, patient recruitment, contracting & budgeting, quality & compliance, and project management. 

Contracting

Our dedicated contracts team is well versed in clinical trial contracting to provide the best possible protection. Our services are technology-based in order to best manage the contracting process and status updates.

Budgeting

We offer an experienced and unbiased team, building global site budgets using an established database for fair market value and a procedure-level understanding of each protocol. We’re able to work with rate cards to negotiate budgets and have a regulatory focus in the EU and US providing >800 regulatory reports annually to meet Sunshine and EFPIA standards, customised to sponsor specifications

ICON’s Investigator Payments group is high performing in administering Investigator payments with >90% of payments made within 30 days of invoice receipt. Services extend to building study budgets, transparency reporting of payments, and clinical study tax management. 

In this section

Connect with us

Related information:

drug-dev-patient-centricity

The solution to persistent startup bottlenecks? Refocusing on site centricity

Study startup, and specifically, feasibility, site selection and activation, remains one of the most critical yet challenging early phases of clinical trial delivery. The solution to persistent startup bottlenecks? Refocusing on site centricity.
doctors_people_monitor_computer

Interview series: Part 1 of 5 - Rethinking site activation to cut startup timelines

How contract standardisation, proactive budget alignment, and AI-enabled negotiation tools can reduce site activation delays and turn agreements into strategic accelerators.
blog

Interview series: Part 2 of 5 - Closing communication gaps during study startup

Why persistent communication breakdowns between sponsors, CROs, and sites undermine startup efficiency—and how bidirectional, site-informed engagement models can improve collaboration and momentum.
thumbnail

Interview series: Part 3 of 5 - Applying AI to reduce administrative burden without losing the human touch

How practical AI applications can streamline contracts and startup workflows while preserving the central role of investigators, site staff, and patient relationships.
Team of clinical trial specialists

Interview series: part 4 of 5 - Why startup timelines are worsening – and how to reduce the trend

The operational pressures driving longer activation timelines, from protocol complexity to site competition, and how earlier, more flexible site engagement can restore momentum.
Medical professionals discussing trial data

Interview series: Part 5 of 5 - Centering site experience to accelerate site activation

How sponsor and CRO practices that prioritise site needs, clarity, and partnership can strengthen trust, sustain momentum, and speed activation.
Virtual document review for study startup

Examining the growing delays in clinical trial start-up

Brian Mallon discusses the increasing timeframe from site selection to full activation, including the issues contributing to the delay and measures to address them.
clinical-globe-netwrork

New ICON survey shows sites face growing delays and communication gaps during study startup

ICON’s survey of more than 100 investigators and site leaders reveals persistent bottlenecks in study startup driven by contract and budget delays, slow activation timelines, and insufficient collaboration from sponsors and CROs.
digital data on laptop

Smarter starts, stronger trials: How data is driving faster site activation

Feasibility, site selection and study startup are among the most complex areas of clinical development, yet they remain stubbornly inefficient. ICON’s Brian Mallon explores how sponsors and CROs are leveraging AI, predictive analytics and integrated data environments for faster, more predictable trial delivery and stronger site partnerships. Read the full article.

Accellacare site resourcing

Site engagement
two people in business meeting

Talking the talk

At ICON ensuring scientifically representative participation is not a stand-alone initiative, it’s embedded into every trial we support, shaping smarter, faster, higher-quality research. We start with the patient’s voice.